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Abstract The approval and differentiation of new compounds in clinical devel-
opment often demands non-inferiority trials, in which the test drug is compared
against a reference treatment. However, non-inferiority trials impose major opera-
tional burden with serious ethical and scientiﬁc implications for the development of
new medicines. Traditional approaches make limited use of historical information
on placebo and neglect inter-trial variability, relying on the constancy assumption
that the control-to-placebo effect size is maintained across trials. We propose a
model-based approach that overcomes such limitations and may be used as a tool to
explore differentiation during clinical development. Parameter distributions are
introduced which reﬂect the heterogeneity of trials. The method is illustrated using
data from impetigo trials. Based on simulation scenarios, this Bayesian technique
yields a deﬁnitive, consistent increase in the statistical power over two accepted
statistical methods, allowing lower sample size requirements for the assessment of
non-inferiority.
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Medical and health care policies often demand drugs to be effective, rather than just
efﬁcacious. However, there are circumstances in which the assessment of
effectiveness implies demonstration of non-inferiority rather than superiority.
These considerations are relevant to product differentiation when the experimental
compound is not expected to outperform the established standard of care based on
the primary protocol endpoint [1]. Instead, the treatment is meant to offer ancillary
advantages in terms of its clinical pharmacology proﬁle, safety, tolerability, cost, or
convenience. In this situation, demonstrating a statistically signiﬁcant effect size
imposes huge sample sizes, as the difference in efﬁcacy between the two treatments
is small [2].
Non-inferiority has been the subject of late drug development in statistical and
clinical trial publications. However, it has clear implications for early clinical
studies when standard of care is effective and add-on or combination therapy is to be
used as primary indication. The concept of non-inferiority trials was introduced to
compare a so-called golden standard against the new drug, excluding the
requirement for comparison against a placebo arm [3, 4]. More recently, regulatory
guidance has been issued on the use of concurrent control to support the conclusion
that the new test drug is also effective [5, 6]. This requirement entails operational
challenges, including ﬁnancial and ethical considerations, with direct implications
for the design of clinical trials aimed at the differentiation of novel compounds.
Despite the justiﬁcation for the use of an active comparator, the availability of a
placebo arm still constitutes important evidence of drug response and, of course,
enables establishing assay sensitivity as well as the underlying exposure–response
relationship.
Given that non-inferiority trials often do not include placebo, uncertainty exists
about the true magnitude of the effect of each individual treatment. This represents a
major challenge for decision making in early clinical development, including further
understanding of the dose-exposure–response curve in the population of interest. In
fact, based on current practice, one has partial evidence about the overall
distribution of the effect size by the time drugs reach the market and only a few
clinical trials have been performed. In addition, it has been established that patient
population and other factors, including placebo effect also contribute to variability
in treatment response. The consequence of this uncertainty is an inﬂation of the size
of such trials, which other than just being expensive raise the ethical question about
the need to enrol so many subjects to reach the level of evidence required for non-
inferiority. Moreover, these hurdles prevent a meaningful evaluation of the
therapeutic value of the compound prior to Phase III.
From a methodological perspective, non-inferiority trials [7] require the new
compound to be statistically non-inferior relative to the active comparator (e.g. at
least 90% efﬁcacy). Additionally, superiority to placebo (of at least 50% in terms of
clinical efﬁcacy, for example) [5, 6] may be required for regulatory purposes in
therapeutic areas such as psychiatry. In the literature related to non-inferiority trials
with binary outcome, which is further considered in this manuscript, the assessment
of non-inferiority involves test statistics such as success proportion or odds ratio for
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123the different treatment arms. Efﬁcacy endpoints may be the proportion of cured
patients or the reduction in the rate of adverse events or mortality after a predeﬁned
treatment period. Comparison between treatment arms is then performed using
statistical hypothesis testing [8]. Utilisation of historical information is limited or
absent: previous trials may be simply used to work out an estimate of the placebo
effect in the current non-inferiority trial, should it contain no placebo arm. This is
also known as putative placebo analysis [9, 10]. Furthermore, traditional methods
do not address the issue of inter-trial variability. On the contrary, they rely on the
so-called constancy assumption, that is, that the historical difference between
control and placebo treatment arms is also maintained in the current trial [8, 11].
Such effect size is in turn used to estimate the non-inferiority margin for the
comparison between treatment arms [8]. Moreover, testing multiple hypotheses
(non-inferiority to the active control and superiority to placebo) is made difﬁcult by
the frequentist nature of such analyses. If fact, the reliance on P-values has been
widely criticised for comparison purposes [12].
To date, most of the debate concerning the differentiation of treatment effect in
clinical development revolves around the question whether proving non-inferiority
is feasible or ethical. Instead, we feel that attention should focus on how to properly
analyse trial data, exploit the available knowledge (also from past trials), obtain
realistic estimates of required sample size to plan a non-inferiority trial and most
importantly demonstrate whether differentiation is achievable at early stages of
development. The aim of our investigation is therefore to (i) develop a general
Bayesian framework for non-inferiority (and possibly superiority) assessment, (ii)
show its ability to incorporate data from historical trials, and (iii) compare the
performances of the proposed approach to two accepted statistical methods, in terms
of required sample size and power.
A Bayesian mixed-effects model for binary endpoints is proposed that
overcomes the limitations of traditional methods. Test statistics are derived
through logistic regression. The constancy assumption is relaxed by introducing
parameter distributions, which reﬂect the heterogeneity of available trials. Of note,
the Bayesian approach adopted here enables the estimation of the probability that
the experimental drug is non-inferior to the active control while being superior to
placebo, through the joint posterior distribution obtained from the new and previous
trials. Moreover, it is possible to account for the uncertainty in the estimation of the
inter-trial variability, which is not directly feasible in a non-Bayesian or frequentist
context. A comprehensive assessment of uncertainty is a key factor in the
evaluation of non-inferiority. The possibility to make well-deﬁned probability
statements without resorting to null hypotheses and P-values is therefore a further
advantage.
These concepts are illustrated by the analysis of non-inferiority of two treatment
options for impetigo. Impetigo is a staphylococcal skin infection that is particularly
frequent in children for which several treatment options are available, including
topical creams and oral antibiotics [13]. Based on a recent review, it was possible to
implement the proposed method in conjunction with a retrospective analysis of 13
clinical trials [14] and two trials involving an investigational compound. Subse-
quently, results from simulations were compared to two accepted statistical
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of the traditional frequentist method based on difference of sample proportions with
putative placebo analysis [10, 11].
Methods
Patients and data
Data from two Phase III trials of an experimental drug, as well as data from 13 trials
reported in a review by Koning et al. [14] were analysed (Table 1). The clinical
endpoint was success or failure after 5 days of treatment. The trials from literature
involved either placebo, fusidic acid or both. The other two studies were a
randomised, double-blind trial of the test drug vs. placebo (study A) and a
randomised, observer-blind trial of the test drug vs. fusidic acid (study B). Further
details can be found in the GlaxoSmithKline clinical trial register (http://
www.gsk-clinicalstudyregister.com/ﬁles/pdf/21118.pdf and http://www.gsk-clinical
studyregister.com/ﬁles/pdf/21117.pdf). Overall, 18 treatment arms were considered
(6 placebo, 10 fusidic acid, 2 test drug). In each trial, the primary outcome was the
proportion of clinical cure at a predeﬁned study day, reported as the observed
number of clinical successes divided by the arm size in Table 1.
Bayesian population model of available trials
A Bayesian model was developed that does take into account historical trials but
without resorting to the constancy assumption. Here, ‘‘population’’ refers to the
collection of available trials, not patients. Probabilities of clinical success were
obtained for each trial of the population using logistic regression. All trials are seen
as if we were observing ‘‘noisy’’ versions of a true, typical trial. More precisely,
within each trial, probabilities for placebo, comparator and test drug are modelled as:
logitðp
ðkÞ
p Þ¼a þ sk
logitðp
ðkÞ
c Þ¼a þ b þ sk
logitðp
ðkÞ
t Þ¼a þ c þ sk
8
> <
> :
ð1Þ
where k = 1…K; k represents each individual trial and K the total number of trials.
The subscripts p, c and t indicate placebo, comparator and test compound,
respectively.
Success probabilities in actual trials are simply obtained by inverting the logit
relationship. The characterisation of the typical trial is obtained by removing the
random effects sk from Eq. 1. Therefore, the ﬁxed-effects a, b and c, characterising
the success probabilities of the typical trial, are termed typical parameters. The
typical probabilities are easily obtained as:
pp ¼ ea
1þea pc ¼ eaþb
1þeaþb pt ¼ eaþc
1þeaþc ð2Þ
in which the superscript (k) has been dropped.
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to bias estimates of the typical probabilities. Random trial effect sk (the ‘‘noise’’)
had a normal prior with zero mean and variance x
2. Note that, although different
distributions could be used for the parameters of the logit relationship, the normal
Table 1 Synopsis of experimental impetigo trials. Historical trial details can be found in the review by
Koning et al. [14]
No. Study Placebo Fusidic acid NCE
1 Christensen (1994) [16] – 2 to 3 td, evaluation
time not reported
105/128
–
2 Eells (1986) [17] 3 td, day 8
8/19
––
3 Gilbert (1989) [18] – 3 td, day 7
6/11
–
4 Gould (1984) [19] 1 td, evaluation time
not reported
7/21
––
5 Koning (2002) [20]3 t d ? povidone-iodine
2 td), day 7
10/80
3t d? povidone-iodine
2 td, day 7
42/76
–
6 Moraes Barbosa
(1986) [21]
– 3 td, day 7
10/12
–
7 Morley (1988) [22] – 3 td, day 6 to 8
45/51
–
8 Park (1993) [23] – 20 to 40 mg/kg/d, day 7
11/18
–
9 Rojas (1985) [24] 3 td, day 7 to 12
15/52
––
10 Ruby (1973) [25] 3 td, day 5
0/20
––
11 Sutton (1992) [26] – 3 td, day 8
90/93
–
12 Vainer (1986) [27] – Dosing not reported, day 7
26/43
–
13 White (1989) [28] – 3 td, day 7
33/49
–
14 GSK A 2 td, day 7
37/73
– 2 td, day 7
119/140
15 GSK B – 3 td, day 9
150/156
2 td, day 7
315/320
NCE new chemical entity, td times per day, day the evaluation time of the clinical endpoint
Cure rates are reported as observed number of clinical successes divided by the arm size
J Pharmacokinet Pharmacodyn (2011) 38:595–612 599
123distribution is an obvious choice (see for example [15]). In order to account for
uncertainty in the inter-trial variability, the parameter x
-1 (inter-trial standard
deviation) was assigned a uniform prior distribution, as suggested in [29]. The range
of the uniform density was set wide enough to be uninformative while avoiding
unreasonably high values of x
-1. This was achieved by setting the lower bound to
zero and the upper bound to ten times the value of a preliminary restricted
maximum likelihood estimate of x
-1.S e e[ 29, 30] for an extensive discussion on
the choice of prior distributions for variance parameters in hierarchical models.
Non-inferiority and effect retention test
Differently from current practice, our purpose is not only to assess non-inferiority of
the experimental drug with respect to the active control, but also to quantify
superiority of the new drug with respect to placebo in terms of effect retention (the
fraction of control-to-placebo effect size retained by the new compound). Therefore,
we deﬁne the following test statistics:
T1 ¼ pt   l1pc
T2 ¼ð pt   ppÞ l2ðpc   ppÞ ð3Þ
where l1 is termed non-inferiority margin, whereas l2 is the preservation factor (i.e.
fraction of the control-to-placebo effect size retained by the test drug) [8]. In
general, effect fractions l1 and l2 range between 0 and 1.
Although recommendations from the International Conference on Harmonization
and the European Medicines Agency suggest that the non-inferiority margin l1
should be justiﬁed on both statistical and clinical grounds [5, 6, 31], its proper
choice is still matter of debate [32, 33]. Widely used values have been reported to be
80 or 90% for l1 [11, 15], and 50% for l2 [11].
In order to conclude non-inferiority and effect retention, we calculate the
probability that both T1 and T2 are greater than zero, given the current data. This is
readily achieved using the joint posterior density of T1 and T2:
PðT1 [0;T2 [0jdataÞ¼
Z 1
0
Z 1
0
fðT1;T2jdataÞdT1dT2 ð4Þ
Such probability is then compared to the threshold value Pcutoff in order to accept
or reject the experimental drug. Throughout this investigation, we have used 90 and
50% for l1 and l2 respectively, and 95% for Pcutoff.
Prospective use in clinical trials: statistical analysis
It is of interest to evaluate this approach prospectively, by means of simulation
scenarios. Simulations also enable the assessment of properties such as speciﬁcity
and sensitivity, as well as estimation of the required sample size for a new trial. We
compared our model to a non-hierarchical Bayesian [15] and a standard
implementation method based on the comparison of sample proportions of clinical
success, with putative placebo analysis [10, 11].
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simulated benchmark:
1. The Bayesian population method (Eqs. 1–4).
2. A Bayesian, non-hierarchical method proposed by Simon [15]. The method was
originally developed for binary outcome data, which approximates log odds of
failure by the assumption of a normal distribution. We centred the prior of
parameter b (representing the comparator-to-placebo effect size) around the
true effect size used in simulation, and assigned a small standard deviation
(33% relative to the prior mean). Parameters a (placebo effect size) and c (test
drug-to-placebo effect size) were assigned uncorrelated, non-informative
normal priors. Acceptance of the test drug was checked by evaluating T1 and
T2 using probabilities from the model, and comparing P(T1[0, T2[0 | data)
(Eq. 4) with Pcutoff.
3. A traditional analysis (‘‘standard method’’) based on the comparison of sample
proportions of clinical success, with putative placebo [10, 11]. Test statistics T1
and T2 were calculated as point estimates using Eq. 3: success probabilities pc
and pt were estimated from data of the non-inferiority trial, whereas (pc – pp)
was set to the true comparator-to-placebo effect size used to simulate data.
Estimates of T1 and T2 (^ T1 and ^ T2 respectively) were compared against their
null distribution H0, i.e. the distribution of estimates under the null hypothesis
that T1 = 0 and T2 = 0. The test drug was then accepted if
p ¼
Z^ T2
 1
Z^ T1
 1
fðT1;T2jH0ÞdT1dT2 ð5Þ
was greater than Pcutoff. Note that, because of the different nature of the standard
analysis with respect to the two Bayesian alternatives, the acceptance test has to be
performed through a P-value (Eq. 5) rather than a posterior probability (Eq. 4).
Table 2 reports the values of typical probabilities for the analysis of Type I error
and power. Although both the non-hierarchical Bayesian and the standard method
account for success probabilities only in the non-inferiority trial, in the former
approach historical information is used to elicit prior distributions, whereas in the
latter it serves to perform the putative placebo analysis, by means of the constancy
assumption.
Simulation study: design scenarios
We have built a benchmark by simulating different real-life scenarios. Four design
features were considered: sample size of the non-inferiority trial (5 choices),
number of available historical trials (6 choices), sample size of historical trials
(2 choices) and inter-trial variability (2 choices). By combining such features, we
obtained 5 9 6 9 2 9 2 = 120 scenarios. For each of them, 1,000 simulations
were run. Table 2 reports design values used to simulate datasets. Values of effect
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hierarchical structure, we used the model to generate datasets. However, for
fairness, we also analysed the case of no inter-trial variability. Design characteristics
that were investigated are further summarized in Table 3. Scenarios were
categorized into six groups and include:
a. Sample size: Non-inferiority trials were simulated using 100, 200, 300, 400 and
500 total patients, equally randomized between the two treatment arms (active
comparator and experimental drug).
b. Number of available historical trials: Table 3 shows the alternatives that were
considered. For case A, the only available historical trial featured a single
placebo arm, whereas in case B a comparator-vs.-placebo trial was also
simulated. In the remaining cases, we simulated placebo-only (P), comparator-
only (C) and C-vs.-P trials in equal proportion.
c. Sample size of historical trials: Historical trials were simulated using 50 and
200 total patients in cases B to F, with equal randomization between the two
treatment arms (placebo and active comparator). In case A, 25 and 100 patients
were simulated for the placebo arm.
Table 2 Synopsis of the design
characteristics for the analysis of
Type I error and power
Analysis Design characteristic Value
Type I error pp 0.5
pc 0.625
pt 0.5625
Power pp 0.5
pc 0.9
pt 0.9
Both
l1 90%
l2 50%
Pcutoff 95%
Sample size of non-inferiority trial 100
200
300
400
500
Number of available historical trials 1
2
3
6
12
18
Sample size of historical trials 50
200
Inter-trial variability (x
2)0
0.1
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variability. In the former case, a deviation of ±30% from a hypothetical
placebo success probability of 0.5 (equivalent to x
2 = 0.1) was used. Similar
results were obtained with different values of inter-trial variability. Note that, in
general, the value of x
2 cannot directly be interpreted as variability in
probability, given the ‘‘warping’’ introduced by the logit operator.
Software implementation
Fitting of the Bayesian population model was performed using WinBUGS 1.4.3
[34], the Bayesian non-hierarchical method [15] and the standard analysis [10, 11]
were implemented using R 2.8.0 [35]. In addition, R was used to calculate
probability integrals (Eqs. 4, 5), as well as to obtain graphical summaries.
Results
Model evaluation
The Bayesian mixed-effects model was estimated from the 15 trials in Table 1.
These trials involved either placebo, fusidic acid or both. Summaries of the posterior
distributions are reported in Table 4 for typical parameters a, b, c, typical
probabilities pp, pc, pt, inter-trial variability x
2 and test statistics T1 and T2.
Parameters were satisfactorily estimated despite the availability of only 1 or 2 arms
for each trial. As expected, standard deviations of typical success probabilities are
relatively small (24.57%, 7.28%, 8.13% of their respective posterior means), since
all trials contribute to their estimation.
Model performance and the goodness-of-ﬁt were obtained by plotting the
observed proportion of clinical success against the effect distribution for each arm in
each trial (Fig. 1). The estimated proportions were satisfactory, with observations
lying well within the support of the posterior distributions. The width of posterior
distributions reﬂects the different number of subjects in each arm: the larger the arm
size the narrower its associated posterior distribution, meaning less uncertainty
about the effect magnitude.
Furthermore, we assessed the consistency of model simulations with respect to
the observed data by performing a predictive check, that is, by calculating the
Table 3 Summary of available
historical trials in the simulation
benchmark
Label Total trials P-only trials C-only trials C-vs.-P trials
A1 1 0 0
B2 1 0 1
C3 1 1 1
D6 2 2 2
E1 2 4 4 4
F1 8 6 6 6
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(also termed predictive distributions) (Fig. 1). In principle, data simulated from the
model should agree with the observed data, if the parameter estimates are realistic.
In view of such considerations, predictive checks differ conceptually from usual
goodness-of-ﬁt plots, and therefore represent an additional diagnostic tool. Note that
the larger width of predictive distributions with respect to posterior distributions is
not due to imprecision in parameter estimation, but to the fact that predictive
distributions incorporate inter-trial variability.
Observe that, in a typical trial, the probability that the experimental drug is non-
inferior to the active comparator while being superior with respect to placebo is
96.8%, i.e., greater than the acceptance cut-off of 95% (Table 4). Such posterior
probability is obtained by evaluating Eq. 4 on the joint posterior density of T1 and
T2 (Fig. 2). Based on these results, we would accept non-inferiority of the new
compound.
We are well aware of the potential pitfalls of analyzing historical information,
such as exchangeability and publication bias. A thorough coverage of such topics is
beyond the scope of this work, as extensive literature on the topic exists (see for
example [30, 36]). To illustrate our statistical procedure, we considered all trials as
exchangeable. The interested reader is referred to [14], which details the
characteristics of the analyzed impetigo trials. Differences among trials (e.g. due
to different standards of care, patient population, dose, drug exposure, etc.), which
Table 4 Summary of posterior distributions and non-inferiority analysis on the experimental impetigo
trials
Quantity Mean SD 2.5% Median 97.5%
Posterior summaries
a -0.480 0.423 -1.330 -0.450 0.219
b 1.875 0.312 1.300 1.873 2.473
c 2.086 0.323 1.448 2.098 2.724
pp 0.387 0.0952 0.209 0.389 0.555
pc 0.795 0.0579 0.667 0.801 0.890
pt 0.823 0.0669 0.665 0.830 0.925
x
2 1.884 0.947 0.717 1.670 4.223
T1 0.108 0.0543 -0.00869 0.111 0.203
T2 0.232 0.0500 0.131 0.234 0.330
Non-inferiority analysis
l1 90%
l2 50%
Pcutoff 95%
P(T1[0, T2[0 | data) 96.8%
Observe that in a typical trial, the probability that the experimental drug is non-inferior to the active
comparator while being superior with respect to placebo is 96.8%, i.e., greater than the acceptance cut-off
of 95%
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Fig. 1 Results obtained from ﬁtting the Bayesian population model to the 15 experimental datasets.
Placebo, control, and test drug are grouped together, clockwise. Each panel shows the posterior of the
success probability, the posterior predictive density, and the observed success proportion. Within each
treatment group, panels are ordered in increasing effect magnitude
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123are easily encountered when multiple historical studies are considered, are assumed
to be captured by the inter-trial variability parameter.
Simulation study
To assess the robustness of our method, a variety of design scenarios were
considered, including different sample sizes of the non-inferiority trial, amount of
available historical information and inter-trial variability.
The comparison between the three methods is summarised in terms of sample
size to achieve a given statistical power (Fig. 3), as well as Type I error and power
vs. sample size (Fig. 4). The simulated scenario depicted in Fig. 3 refers to the case
of 2 historical trials, with sample size of historical trials equal to 50 subjects, and a
deviation of ± 30% from a hypothetical placebo success probability of 0.5
(equivalent to x
2 = 0.1). In Fig. 4, only the scenario with 50 patients in each
historical trial is shown, with supporting data from 2 or 12 historical trials. Similar
results were obtained in the remaining scenarios. Moreover, evaluation of different
values of inter-trial variability did not yield appreciable differences in the results.
The Bayesian mixed-effects method yielded a deﬁnitive and consistent advantage
over the standard and non-hierarchical Bayesian techniques, achieving a consid-
erable reduction in the sample size for the new trial (Fig. 3). With respect to the
non-hierarchical Bayesian method, for example, about one hundred patients would
be saved if 80% statistical power were required in the planned non-inferiority trial.
Moreover, it should be noted that sample size would exceed 500 subjects to meet the
same criteria based on the standard methods currently used.
As can be noted in Fig. 4, all three methods achieved Type I errors between 1%
and 6%. However, for a given sample size, our model yielded a considerable gain in
power to detect non-inferiority, which is in accordance with the results of Fig. 3.
0
.
0
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.
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0
.
2
0
.
3
0
.
4
T
2
−0.1 0.0 0.1 0.2 0.3
T1
Fig. 2 Joint posterior density of
the two test statistics T1 and T2
(Eq. 3), obtained by samples.
The probability that both
statistics are greater than zero
(Eq. 4) is 96.8%. The associated
region of the posterior density is
represented in magenta (Color
ﬁgure online)
606 J Pharmacokinet Pharmacodyn (2011) 38:595–612
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allows increased statistical power not only because estimates of effect sizes are
made more precise (due to the larger amount of data contributing to their
calculation), but also because heterogeneity of trials is accounted for, which results
into a more accurate estimation of the true (i.e., typical) effect sizes.
Discussion
The increasing expectation of patients and health care policy makers on the
effectiveness and improved beneﬁt-risk ratio of novel therapeutic agents has
prompted the demand for comparative trials in which the superiority of a treatment
may not be the primary aim of a protocol. Indeed, there may be circumstances in
which a non-inferiority analysis, as opposed to superiority, is unavoidable: fewer
side effects, less invasiveness, reduced costs and treatment convenience [37]. This
scenario has become more and more relevant with the search for product
differentiation, a requirement which needs to be explored already in the early
stages of development.
Despite the arguments for the use of active-controlled non-inferiority trials to
compare a new drug with existing therapeutic solutions, common concerns are the
design requirements and the impossibility to fully characterise the exposure–
response relationship. In addition, as indicated previously, the improper or
incomplete use of available information concerning placebo response and efﬁcacy
of comparators raises not only ethical but also statistical questions regarding the
estimates of effect size [3, 38]. We have addressed these issues by developing a
general Bayesian method to compare a candidate drug to an established comparator
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hypothetical placebo success probability of 0.5
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123as well as placebo, in a way which structurally exploits historical information and
potentially provides the basis for subsequent evaluation of the exposure–response
curve in the target population.
Although it would be possible to elicit estimates of effect sizes from past trials, as
it is often done with historical placebo, we do not advocate such a strategy, which
may be unpractical and not fully acceptable in a regulatory setting. Instead, we
directly incorporate all available information in our model, by means of a
hierarchical model structure. Such information may come from past comparator vs.
placebo studies as well as from placebo arms in trials with different controls. Our
purpose is to ‘‘borrow strength’’ from previous trials while still accounting for their
inherent diversity. Moreover, it should be noted that this approach enables the
incorporation of pharmacokinetic-pharmacodynamic modelling concepts into the
evaluation of non-inferiority trials. An exposure–response curve may be inferred
even if a placebo arm for the current non-inferiority trial is not available. On the
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608 J Pharmacokinet Pharmacodyn (2011) 38:595–612
123other hand, there are also circumstances, such as in oncology and cardiovascular
trials, in which patients must be assigned treatments with proven efﬁcacy [1, 39,
40]. Our approach allows estimation of the placebo effect in the non-inferiority trial
even if a placebo arm is not present. In this respect, we need not resort to the so-
called constancy assumption, that is, that the difference between control and placebo
effect of a generic past trial is retained in the current clinical setting. Unfortunately,
most traditional putative placebo analyses still seem to lean on this widely-criticised
assumption [8, 11, 41].
Another common concern relates to the underlying statistical requirements,
which cause non-inferiority trials to be ‘‘large trials’’ [42–44] and their tendency, in
life-threatening diseases, to expose a large fraction of patients to serious or fatal
conditions given the uncertainty of the beneﬁt of the new treatment [45]. However,
convincing evidence can be obtained by collecting information from possibly
smaller trials [45]. As illustrated here, the integration of all available information
from other placebo- or active-controlled trials proves useful in reducing the planned
sample size. Therefore, this Bayesian approach circumvents the aforementioned
concerns, enabling efﬁcient use of patients participating in non-inferiority trials.
Remarkably, our method is also easily applicable to superiority analyses, although
these features have not been explored here. For instance, a simple superiority test
could be obtained by setting l1 = 1 and checking if the probability that T1 is greater
than zero overcomes the threshold Pcutoff. The effect retention statistics T2 would not
be necessary, since superiority implies effect retention. Furthermore, the concepts
may be easily extended to account for continuous endpoints: e.g., the mean response
in a treatment arm may be modelled as a linear or nonlinear function of ﬁxed
effects, random trial effects, and measurement error.
The ﬁnal assessment of the expected effect size relies on two test statistics,
namely the probability that the experimental drug is non-inferior to the comparator
and that the experimental drug retains a certain portion of the comparator’s effect
with respect to placebo. Usually, such requirements are stated in terms of the null
hypothesis to be rejected. In many cases, indeed, the latter test is implicitly
performed as part of the former, that is, the non-inferiority margin is actually
estimated by imposing a constraint on the effect retention. This two-at-the-price-
of-one approach may be misleading and rather cumbersome. The clear-cut
approach, adopted in this modelling exercise, is to compute the posterior probability
that both non-inferiority and effect retention are guaranteed.
From a regulatory standpoint, it should be noted that despite the acceptance by
regulatory authorities, the use of traditional methods may result in biased and/or
imprecise estimates of the treatment effect size, which has direct implications for
the overall statistical power. The additional drawback currently accepted methods is
an inefﬁcient exploitation of sample size properties: regulatory requirements
mandate that a non-inferiority trial be repeated, in order to conﬁrm the non-
inferiority assessment. An integrated analysis of all available data, including
information from past studies, enables increased power to detect small effect sizes
as well as to efﬁciently estimate the sample size for a future non-inferiority trial.
The aforementioned limitations are overcome by the approach proposed here and as
such can be considered suitable for adoption by regulatory boards.
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123From the above, it is evident that current standards the analysis of non-inferiority
trials represent not only a scientiﬁc burden in clinical research. They also prevent
further attempts to differentiate new medicines prior to approval. Thus far, this
subject has remained beyond the realm of clinical pharmacology, with compounds
progressing without clarity about the underlying exposure–response curve and
consequently about the expected performance of the novel treatment. A paradigm
shift is required to address unmet medical needs. Non-inferiority comparisons are
useful and clinically meaningful. However, the level of evidence and methods
required for such an evaluation cannot continue to neglect the need to accurately use
existing information, optimise study design and characterise the exposure–response
relationships of these compounds. Clinical differentiation and quantitative assess-
ment of the characteristics of a medicinal product ought to result from an integrated
analysis of available evidence and as such, efforts must consider historical
information.
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